Bargain hunting for biotech stocks
28:41
IP strategy for biotech startups
1:31:21
Пікірлер
@legendhasit2568
@legendhasit2568 5 күн бұрын
Great examples, very helpful
@SH4DYBR4DY
@SH4DYBR4DY 7 күн бұрын
Would love to see a close out video on recent news about Aducanumab and also any thoughts you have on Lecanemab's approval and prosects.
@vitorniskier
@vitorniskier 10 күн бұрын
Awesome video! Cheers from Brazil.
@mauriziopilato6210
@mauriziopilato6210 19 күн бұрын
Would you be so kind to valuate Cassava Sciences. Small Biotech in the Alzheimer's Space. Thx.
@PirateSpaceCat
@PirateSpaceCat Ай бұрын
💯💯💯
@LawrenceFagan
@LawrenceFagan Ай бұрын
Thank you for making.
@bdml77
@bdml77 Ай бұрын
Nobody is holding a short position for years...misleading video. You absolutely can short biotechnology successfully because most of these companies are unprofitable and in debt, but it must be a quick trade.
@Travesten
@Travesten Ай бұрын
Cereno Scientific NeXT ❤
@devins1195
@devins1195 Ай бұрын
I’ve been value hunting biotech recently. I currently have VNDA, SPRY, LENZ. ACTN, ADCT. Lots of mature potential going.
@vasiliikacman6005
@vasiliikacman6005 2 ай бұрын
Yes, content level is beyond imagination!
@vasiliikacman6005
@vasiliikacman6005 3 ай бұрын
Such a great videos! Thank you so much for sharing your knowledge! Hope you will not abandon this channel
@dessanguyen
@dessanguyen 3 ай бұрын
This is a supremely helpful video. Thank you! We hope you come back ❤
@dw5107
@dw5107 3 ай бұрын
Why is this old information still on here?!
@manesarkissian3419
@manesarkissian3419 4 ай бұрын
Thank you so much for these amazing series! Happily subscribed.
@dessanguyen
@dessanguyen 4 ай бұрын
These videos are amazingly informative, thank you so deeply for your efforts and generosity
@jedidiahmck
@jedidiahmck 5 ай бұрын
What the heck man. This stuff is great, I really don’t get the lack of attention to this channel.
@AJ-yo7rb
@AJ-yo7rb 6 ай бұрын
You need to keep this channel going, I’m not new to trading but the things you teach are excellent I learn a lot from you! It’s sad that people don’t want to learn they just want easy money and ad revenue dictates that by giving a great channel less views… But you are a great resource and I hope you keep the content going.
@thestockfiend9967
@thestockfiend9967 6 ай бұрын
Great stuff would like to see the next part
@thestockfiend9967
@thestockfiend9967 6 ай бұрын
High quality content
@user-ct4wz3pl1l
@user-ct4wz3pl1l 6 ай бұрын
Why’d you stop making videos
@Levnerad
@Levnerad 6 ай бұрын
Underwhelming talk. Very generic and useless honestly
@Nino21370
@Nino21370 7 ай бұрын
What tool did you use for the model?
@jaydee18828
@jaydee18828 7 ай бұрын
Very helpful video, thank you! Do you know of any good resources to help develop assumptions to project any post-approval R&D costs?
@boblawblaw6185
@boblawblaw6185 7 ай бұрын
in hindsight the downturn was caused by a lot of small early clinical to preclinical start up going public, receiving mountains of cash from braindead investors then those investors crying after not following the golden rule of biotech/pharma "90% of drugs fail to get through the clinic" So it doesn't seem like to me biotech had the problem , the problem are venture capital bros who don't understand what they are investing in because they played they were lucky on the stock market or born into money, or they went to an ivy league school and people gave them money under assumption they were intelligent. The problem was too many stupid people had too much money, and we will see the same exact behavior with AI start ups and it will be even more volatile because they don't have to go through anything like the FDA to get to market. part of our problem is a problem of culture and assuming a lot of money means a person is intelligent or we will keep repeating the same mistakes with every tech sector until we get some better investors, because most won't say it , but most of them want to be the next Martin Shkreli minus the prison.
@michaeldai1999
@michaeldai1999 8 ай бұрын
This case study was fascinating, thanks!
@vhme24
@vhme24 8 ай бұрын
Many thanks Man!!
@willlagergaming8089
@willlagergaming8089 9 ай бұрын
this video prevent degen from turning into serial killer.
@tl5160
@tl5160 9 ай бұрын
As someone who is an early employee of a startup, this video was significantly helpful. Thank you.
@bardacha100
@bardacha100 9 ай бұрын
Question : is there a general rule on whether to start with incidence or with prevalence?
@quietStorm247
@quietStorm247 9 ай бұрын
Do you have any thoughts about Takeda's Qdenga vaccine?
@quietStorm247
@quietStorm247 9 ай бұрын
Thank you for this truly great deep dive into some promising advances. Hoping to hear more about what you think going forward.
@runshen7723
@runshen7723 9 ай бұрын
Great content, thank you Richard!
@olegshakarov5319
@olegshakarov5319 10 ай бұрын
1 year later GRPH remains at $2.56
@Zhugongde
@Zhugongde 10 ай бұрын
Hey, awesome video! I was trying out a valuation for a small biotech and realized that I was having some trouble finding the list price for drugs and information on drug penetration for benchmarking. Is there a database where we can find these values or are they provided in one of the financial statement documents? I apologize if this is a really basic question - my background is in science so I am a bit unfamiliar with the more financial/ cost projection side of things. Thanks in advance!
@jackpaperhands
@jackpaperhands 10 ай бұрын
Legend. Best channel.
@TheTobacko1
@TheTobacko1 5 ай бұрын
look for INVITAE ❤❤❤❤❤❤❤its my absolute favourite healthcare company
@jackpaperhands
@jackpaperhands 10 ай бұрын
Legend. Best channel ever.
@joshsmith5617
@joshsmith5617 11 ай бұрын
Awesome man, thank you so much for this
@moko79
@moko79 11 ай бұрын
great series. I was alarmed, when you mentioned Seres. At first I thought, you are going to talk about Syros (where I am invested in). But I am not english native speaker so I just got it wrong. However I would appreciate your 2 cents regarding Syros Pharmaceuticals (Flagship Pioneering is Co-Founder here).
@krishnahira5061
@krishnahira5061 11 ай бұрын
Great content. Would love to see you cover Argenx
@Ozzie12
@Ozzie12 Жыл бұрын
Thank you for this. Question... I often use operating cash flow for a non-revenue generating companies like biotech. Would that be a reasonable surrogate? I imagine using the income statement might factor in other non-recurring factors? Thanks!
@williamcui5
@williamcui5 Жыл бұрын
Extremely well-structured content. Also, really really legit approach to the analysis. Thanks a lot! Got lucky finding this
@BeyondBorders00
@BeyondBorders00 Жыл бұрын
Great overview. Thank you
@BeyondBorders00
@BeyondBorders00 Жыл бұрын
Great introduction. Looking forward to the additional videos
@mikeechegaray7157
@mikeechegaray7157 Жыл бұрын
Your content is awesome plainly simple
@rttube555
@rttube555 Жыл бұрын
Great summary. Need more videos! 🎉
@rttube555
@rttube555 Жыл бұрын
Great details 👍
@sebastianaguiarbrunemeier9192
@sebastianaguiarbrunemeier9192 Жыл бұрын
Awesome content Richard! Keep the analysis videos coming :-)
@samb3639
@samb3639 Жыл бұрын
I think you should make a video about the biotech sector with its current situation in the disinflation environment (CPI going down) with interest rates peaking with a possible rate pause. Also, the recent banking crisis having a negative impact on biotech. XBI was in an uptrend from the start of 2023 but the recent banking crisis made it come down again.
@blondscientist
@blondscientist Жыл бұрын
Another great video! Thank you! Your channel is in very underrepresented niche and such educational content is difficult to find, especially on how to conduct research before investing. I hope continuing with the channel is worth your time. There is a lot of us grateful on the other side.
@blondscientist
@blondscientist Жыл бұрын
This is amazing content. Thank you so much for sharing your knowledge. This channel is really unique in its offering.